Cubist Systematic Strategies, LLC Cassava Sciences Inc Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $294,527 - $920,918	18,036 New	18,036 $754,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $29,926 - $48,699	-918 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $207,787 - $513,732	-5,651 Reduced 86.03%	918 $40,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $164,276 - $531,864	-3,931 Reduced 37.44%	6,569 $408,000
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $337,575 - $942,060	10,500 New	10,500 $897,000
Q4 2020 Feb 16, 2021	SELL	$6.79 - $12.25 $150,738 - $271,950	-22,200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.86 - $11.51 $63,492 - $255,522	22,200 New	22,200 $256,000

195

13.7M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.